Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Humana Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.17, while Humana Inc trades at $387.78 (market cap $48.96B). The key difference: Humana Inc pays a 0.87% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Humana Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| FEPI | HUM | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $409.42 |
52-Week Low | $38.13 | $163.67 |
Market Cap | — | $48.96B |
Enterprise Value | — | $58.00B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI trades at $41.40, down 2.45% over the past day, with technical indicators signaling a bearish trend. The ETF generates a high yield through weekly covered call distributions, but its concentrated tech holdings and call-writing strategy cap upside potential while exposing investors to net asset value erosion during market downturns. Recent news highlights its 25% yield appeal but cautions on structural limitations.
Outlook remains cautious due to the ETF's high-risk income strategy; opportunities exist for yield-seeking investors comfortable with capped gains and volatility, but risks include underperformance versus benchmarks and NAV decay in declining markets. Investor sentiment is mixed, balancing high income against long-term growth constraints.
Humana (HUM) trades at $395.78, down 2.68% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $10.31, beating expectations, and maintains a P/E of 43.52 and P/S of 0.36. Recent news highlights margin recovery targets and expansion through CenterWell, while investigations into insider sales and cost statements introduce uncertainty.
Outlook is mixed: analyst consensus is $354.33 with 61% hold ratings, reflecting caution despite growth initiatives. Key risks include Medicare Advantage margin pressures and legal scrutiny, but revenue growth to $137.2B in 2026 and a dividend payment in July offer support. Investors should weigh profitability trends against valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
